Bioaffinity Technologies, INC S-1 registration statements

BioAffinity Technologies, Inc. has filed details regarding its Pre-funded Common Stock Purchase Warrant, outlining terms for exercise, pricing, and potential adjustments.

bioAffinity Technologies, Inc. has filed a registration statement for a public offering of common stock and pre-funded warrants to raise approximately $4 million for working capital.

bioAffinity Technologies has filed a registration statement for the resale of up to 497,483 shares of common stock issuable upon the exercise of warrants and conversion of Series B preferred stock.

bioAffinity Technologies, Inc. is offering up to 729,927 shares of common stock and pre-funded warrants in a best efforts public offering to raise approximately $3.4 million, while facing Nasdaq delisting threats.

BioAffinity Technologies, Inc. announced a public offering of common stock and warrants to raise capital, following a reverse stock split and ongoing Nasdaq compliance challenges.

bioAffinity Technologies, Inc. filed an S-1/A registration statement for the resale of up to 32,495,628 shares of common stock by selling stockholders, while facing imminent delisting from Nasdaq and a going concern warning.

BioAffinity Technologies files S-1 to register 12.6 million shares for resale by investors, following recent private placements and facing potential Nasdaq delisting due to bid price and equity deficiencies.

bioAffinity Technologies is offering shares of common stock and warrants to raise capital for working capital and general corporate purposes.

bioAffinity Technologies aims to raise up to $3.5 million through a registered direct offering of common stock, warrants, and pre-funded warrants.

bioAffinity Technologies files an S-1 registration statement for the resale of up to 3,013,951 shares of common stock by selling stockholders after a recent warrant inducement.

bioAffinity Technologies is registering for resale 2.7 million shares of common stock, primarily related to warrants issued in a recent private placement.

bioAffinity Technologies is registering for the resale of up to 1.8 million shares of common stock related to recent private placement transactions involving warrants.

bioAffinity Technologies is registering for the resale of up to 1.63 million shares of its common stock by selling stockholders after a recent $2.5 million private placement.